Destiny Pharma
Skip to content
  • About Us
    • Board of Directors
    • Leadership
    • Scientific Advisory Board
    • History
  • Pipeline
    • NTCD-M3 for Clostridioides difficile Infections
    • XF-73 Nasal for Post Surgical Infections
    • XF-73 for Dermal Infections
    • SPOR-COV™ for COVID-19
    • XF Research Programs
  • Target Markets
    • Clostridioides difficile Infections
    • Post Surgical Infections
    • Dermal Infections
    • COVID-19
    • Anti-Microbial Resistance
  • Our Technologies
    • Biotherapeutics
      • NTCD-M3
      • SPOR-COV™
    • XF Platform
  • Business Development
  • News
  • Investors
    • AIM Rule 26
    • Corporate Governance
    • Share Price Information
    • Regulatory News
    • Constitutional Documents
    • Reports & Presentations
    • Advisers / Shareholder Contacts
    • Analyst Coverage
    • Email Alerts
  • Contact
    • Careers
    • Useful Links
03 Feb 2021 – Destiny Pharma announces Brazilian Patent granted for XF-73 nasal gel
02 Feb 2021 – Destiny Pharma to join panel discussion at the 7th Annual LSX World Congress 2021
02 Feb 2021 – Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board
06 Jan 2021 – Destiny Pharma appoints Stephanie Bewick as Chief Business Officer
05 Jan 2021 – Phase 2b trial of XF-73 completes recruitment
22 Dec 2020 – Update on the recently acquired NTCD-M3 programme
21 Dec 2020 – Destiny Pharma joins the Pharmabiotic Research Institute (PRI)

News

Latest News

  • 03 Feb 2021 – Destiny Pharma announces Brazilian Patent granted for XF-73 nasal gel
  • 02 Feb 2021 – Destiny Pharma to join panel discussion at the 7th Annual LSX World Congress 2021
  • 02 Feb 2021 – Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board
  • 27 Jan 2021 – Destiny Pharma welcomes Matt Hancock’s statement saying G7 will focus on AMR
  • 21 Jan 2021 – Destiny Pharma Investor Presentation
  • 06 Jan 2021 – Destiny Pharma appoints Stephanie Bewick as Chief Business Officer
  • 05 Jan 2021 – Phase 2b trial of XF-73 completes recruitment
  • 22 Dec 2020 – Update on the recently acquired NTCD-M3 programme
  • 21 Dec 2020 – Destiny Pharma joins the Pharmabiotic Research Institute (PRI)
  • 26 Nov 2020 – Destiny Pharma – Result of General Meeting and Total Voting Rights

Archive

2020

2019

2018

2017

2016 & Prior

Destiny Pharma

© All rights reserved.

Powered by WordPress

Destiny Pharma plc
Sussex Innovation Centre
Science Park Square
Brighton
BN1 9SB
UK

Tel: +44(0) 1273 704440

Registered Company
No. 3167025
About Us
Pipeline
Target Markets
Our Technologies
Business Development
News
Investors
Contact
Terms of Use
Privacy Statement